Oruka Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $96.32
- 52-Week Range
- $25.23 – $115.52
- Market Cap
- $6.49B
- P/E (TTM)
- —
- EPS (TTM)
- -2.12
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.39
- PEG Ratio
- —
- Return on Equity
- -18.12%
- Return on Assets
- -13.15%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 29.62
- Debt/Equity
- 0.00
- Total Debt
- $2.93M
- Free Cash Flow
- $-91.81M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $5.58B
Market Snapshot
About
Oruka Therapeutics is a clinical-stage biotechnology company developing innovative biologics for chronic skin diseases. The company focuses on creating long-acting antibody therapies for conditions like plaque psoriasis and atopic dermatitis that require less frequent dosing than current treatments.